The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
about
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersTargeting fibroblast growth factor pathways in prostate cancer.Knockdown of NOB1 expression inhibits the malignant transformation of human prostate cancer cells.Activation of AMPK inhibits TGF-β1-induced airway smooth muscle cells proliferation and its potential mechanisms.
P2860
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The prostate cancer blocking p ...... osine kinase inhibitor TKI258.
@en
The prostate cancer blocking p ...... osine kinase inhibitor TKI258.
@nl
type
label
The prostate cancer blocking p ...... osine kinase inhibitor TKI258.
@en
The prostate cancer blocking p ...... osine kinase inhibitor TKI258.
@nl
prefLabel
The prostate cancer blocking p ...... osine kinase inhibitor TKI258.
@en
The prostate cancer blocking p ...... osine kinase inhibitor TKI258.
@nl
P2093
P2860
P1476
The prostate cancer blocking p ...... osine kinase inhibitor TKI258.
@en
P2093
Axel Haferkamp
Eva Juengel
Georg Bartsch
Igor Tsaur
Jasmina Makarević
Matthias Stastny
Roman A Blaheta
Stefan Vallo
P2860
P2888
P304
P356
10.1007/S10637-012-9851-5
P577
2012-07-17T00:00:00Z